Notably, IMQ also considerably enhanced phosphorylation of STAT3, a key player in the development and pathogenesis of psoriasis and psoriatic-like inflammatory conditions [30,32,33], which was significantly inhibited by CS1, but not Tapinarof treatment (Figure 6B and Figure S4A,B). Here, STAT3 is linked to psoriasis.